← FDA Drug Approvals (Drugs@FDA)

OXBRYTA

NDA · New Drug Application · Sponsor: GLOBAL BLOOD THERAPS · Approved 2021-12-17

Drug application

FDA Application #

NDA216157

Application type

New Drug Application

Brand name

OXBRYTA

Generic name

VOXELOTOR

Active ingredients

VOXELOTOR

Dosage form

TABLET, FOR SUSPENSION

Route

ORAL

Marketing status

Discontinued

Sponsor

GLOBAL BLOOD THERAPS

Manufacturer

Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.

First approval

2021-12-17

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown